Saturday 17 October 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
24.42
0.53
−2.12%
Follow NRIX
| Nov '17 | Nov '18 | Nov '19 | Nov '20 | Nov '21 | Nov '22 | Nov '23 | Nov '24 | Nov '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 2 | 3 | 4 | 3 | 4 |
Altman Z-Score |
— | — | — | 3.68 | 4.73 | 1.20 | (1.36) | 4.68 | 3.77 |
P/S ratio |
— | 0.00 | 0.00 | 37.49 | 41.55 | 15.59 | 4.39 | 26.44 | 17.45 |
Altman Z″-Score (non-manufacturers) |
— | (3.56) | (5.00) | 5.12 | 2.87 | 0.62 | (2.72) | 3.28 | 1.20 |
P/FCF ratio |
— | 1.52 | 1.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (4.92) | (4.92) | (32.61) | (39.99) | (15.87) | 12.66 | (29.59) | (21.61) |
Beneish M-Score |
— | — | — | — | (2.21) | — | — | — | — |
P/B ratio |
— | 0.00 | 0.00 | 2.30 | 3.61 | 1.98 | 1.69 | 2.74 | 2.72 |
Price to Tangible BV |
— | 0.00 | 0.00 | 2.30 | 3.61 | 1.98 | 1.69 | 2.74 | 2.72 |
EV/Sales |
— | 0.00 | 0.00 | 21.71 | 31.61 | 7.59 | 0.65 | 15.27 | 10.39 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (2.04) | (2.04) | (4,835.44) | (11.15) | (1.83) | (0.62) | (4.83) | (3.50) |
EV/FCF |
— | (2.19) | (2.19) | (83.50) | (10.45) | (1.70) | (0.56) | (4.58) | (3.31) |
Quick Ratio |
— | 1.19 | 2.34 | 6.40 | 4.56 | 4.38 | 3.31 | 6.36 | 6.86 |
Current Ratio |
— | 1.24 | 2.44 | 6.70 | 4.70 | 4.51 | 3.40 | 6.46 | 7.02 |
Net Debt/EBITDA |
— | 5.49 | 1.89 | 4.50 | 2.69 | 1.79 | 1.96 | 2.93 | 2.14 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 1.65 | 0.70 | 0.08 | 0.07 | 0.09 | 0.20 | 0.11 | 0.12 |
Operating CF/Net income |
— | 3.36 | (0.03) | 0.00 | 0.72 | 0.89 | 0.57 | 0.89 | 0.94 |
Capex/Depreciation |
— | (0.60) | (0.74) | (1.86) | (0.73) | (1.09) | (1.02) | (1.80) | (1.64) |
| — | 19.94% | 45.89% | (37.19%) | (37.05%) | (55.84%) | (57.10%) | (53.22%) | (49.63%) | |
| — | (41.54%) | (48.52%) | (19.64%) | (26.85%) | (40.37%) | (37.27%) | (37.77%) | (38.96%) | |
ROIC |
— | 0.00% | 0.00% | (445.28%) | (158.17%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (77.00%) | (80.11%) | (16.60%) | (45.74%) | (68.07%) | (63.88%) | (35.76%) | (48.72%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 78.78 | 76.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 108.18% | 144.71% | 373.14% | 391.37% | 477.64% | 245.69% | 406.30% | 377.36% |
Selling, General and Administrative Expense of Revenue |
— | 17.82% | 26.76% | 91.52% | 104.88% | 98.37% | 55.73% | 84.23% | 62.80% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 1.15% | 1.64% | 24.14% | 53.11% | 72.83% | 43.74% | 62.20% | 45.21% |
Graham Net Nets |
— | (1.10) | (1.10) | 0.29 | 0.14 | 0.34 | 0.42 | 0.33 | 0.31 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (4.00%) | (4.00%) | (7.21%) | (9.47%) | (30.10%) | (42.60%) | (13.45%) | (17.98%) |
Free Cash Flow Yield |
— | 65.89% | 65.89% | (0.69%) | (7.28%) | (28.57%) | (26.56%) | (12.61%) | (17.98%) |
Revenue per Share |
— | 13.29 | 9.45 | 1.14 | 0.69 | 0.79 | 1.42 | 0.81 | 0.97 |
Operating CF per Share |
— | (11.24) | 0.18 | (0.01) | (1.97) | (3.29) | (1.50) | (2.57) | (2.88) |
Capex per Share |
— | (0.56) | (0.50) | (0.29) | (0.13) | (0.25) | (0.15) | (0.14) | (0.16) |
Free Cash Flow per Share |
— | (11.81) | (0.32) | (0.30) | (2.10) | (3.54) | (1.65) | (2.71) | (3.04) |
Cash per Share |
— | 13.86 | 11.45 | 17.94 | 6.89 | 6.36 | 5.30 | 9.08 | 6.84 |
Shareholders Equity per Share |
— | (13.08) | (17.53) | 18.52 | 7.98 | 6.25 | 3.69 | 7.85 | 6.22 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (13.08) | (17.53) | 18.52 | 7.98 | 6.25 | 3.69 | 7.85 | 6.22 |
Free Cash Flow |
— | (33.26) | (1.05) | (4.63) | (90.03) | (172.05) | (89.77) | (181.86) | (263.47) |
Working Capital |
— | 7.82 | 23.22 | 253.90 | 244.86 | 247.79 | 208.55 | 523.53 | 520.35 |
Capital Expenditures |
— | (1.59) | (1.65) | (4.55) | (5.66) | (12.24) | (8.40) | (9.27) | (14.00) |
Net Current Asset Value |
— | (41.59) | (62.41) | 192.36 | 176.65 | 205.39 | 140.40 | 477.04 | 457.43 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.04 | 0.05 | 0.26 | 0.19 | 0.32 | 0.11 | 0.17 | 0.17 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.60 | 0.58 | 0.37 | 0.69 | 0.65 | 0.49 | 0.29 | 0.38 |
Cash ROIC |
— | (1,517.52%) | 5.25% | (0.81%) | (14.11%) | (28.07%) | (18.38%) | (16.00%) | (23.28%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 1.93 | 5.92 | 10.58 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 9.23 | 5.03 | 3.65 | — | — | — |
Average Payables |
— | 1.45 | 1.45 | 2.51 | 5.03 | 5.86 | 5.73 | 8.94 | 11.35 |
Average Assets |
— | 22.70 | 44.72 | 220.20 | 436.56 | 446.77 | 386.18 | 512.47 | 678.74 |
Average Common Equity |
— | (47.28) | (47.28) | 116.28 | 316.29 | 323.00 | 252.09 | 363.74 | 532.87 |
Columns are period end dates · fundamentals updated 15 Oct 2026